Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction

[1]  M. Drutskaya,et al.  TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. , 2017, Cytokine.

[2]  Zhe-Sheng Chen,et al.  Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF‐κB Pathway in Colorectal Cancer , 2016, Journal of cellular biochemistry.

[3]  Xiaohu Gu,et al.  Knockdown of biglycan expression by RNA interference inhibits the proliferation and invasion of, and induces apoptosis in, the HCT116 colon cancer cell line. , 2015, Molecular medicine reports.

[4]  C. Cho,et al.  Chronic inflammation and colorectal cancer: the role of vascular endothelial growth factor. , 2015, Current pharmaceutical design.

[5]  Xiaohu Gu,et al.  Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer , 2015, Tumor Biology.

[6]  C. Cho,et al.  Cigarette smoking and gastrointestinal diseases: the causal relationship and underlying molecular mechanisms (review). , 2014, International journal of molecular medicine.

[7]  Xianzhong Meng,et al.  Soluble biglycan induces the production of ICAM-1 and MCP-1 in human aortic valve interstitial cells through TLR2/4 and the ERK1/2 pathway , 2014, Inflammation Research.

[8]  J. Cleveland,et al.  Biglycan Induces the Expression of Osteogenic Factors in Human Aortic Valve Interstitial Cells via Toll-Like Receptor-2 , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[9]  D. Menendez,et al.  The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. , 2012, Cancer research.

[10]  N. Shinohara,et al.  Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells , 2012, British Journal of Cancer.

[11]  Valerie M. Weaver,et al.  The extracellular matrix at a glance , 2010, Journal of Cell Science.

[12]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[13]  J. Newcombe,et al.  Extracellular Matrix in Multiple Sclerosis Lesions: Fibrillar Collagens, Biglycan and Decorin are Upregulated and Associated with Infiltrating Immune Cells , 2010, Brain pathology.

[14]  B. Nordlinger,et al.  Colorectal cancer – Authors' reply , 2010, The Lancet.

[15]  K. Sakamoto,et al.  Targeting NF-κB for colorectal cancer , 2010, Expert opinion on therapeutic targets.

[16]  G. Sethi,et al.  Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. , 2010, Biochimica et biophysica acta.

[17]  B. Nordlinger,et al.  Colorectal cancer , 2010, The Lancet.

[18]  P. Moore,et al.  Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery , 2010, British Journal of Cancer.

[19]  M. Salto‐Tellez,et al.  CD133 expression predicts for non-response to chemotherapy in colorectal cancer , 2010, Modern Pathology.

[20]  A. Jemal,et al.  Worldwide Variations in Colorectal Cancer , 2009, CA: a cancer journal for clinicians.

[21]  L. Hood,et al.  Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. , 2009, Omics : a journal of integrative biology.

[22]  J. Pfeilschifter,et al.  Biglycan, a Danger Signal That Activates the NLRP3 Inflammasome via Toll-like and P2X Receptors* , 2009, The Journal of Biological Chemistry.

[23]  Ling Xia,et al.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.

[24]  E. Van Cutsem,et al.  Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Dick.  Looking ahead in cancer stem cell research , 2009, Nature Biotechnology.

[26]  R. Lüllmann-Rauch,et al.  Biglycan Is Required for Adaptive Remodeling After Myocardial Infarction , 2008, Circulation.

[27]  P. Beale,et al.  A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  F. Izzo,et al.  Phase II evaluation of 90yttrium resin microspheres (sir-spheres) monotherapy in unresectable, heavily pre-treated colorectal liver metastaseses , 2008 .

[29]  P. Dirks,et al.  Cancer stem cells: at the headwaters of tumor development. , 2007, Annual review of pathology.

[30]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[31]  N. Rajamannan.  Calcific aortic stenosis: a disease ready for prime time. , 2006, Circulation.

[32]  K. Brown,et al.  An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. , 2005, Cancer research.

[33]  R. Goldberg,et al.  Colorectal cancer chemotherapy , 2003 .

[34]  J. Parker.  Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein , 2003 .

[35]  R. Goldberg,et al.  Review article: colorectal cancer chemotherapy. , 2003, Alimentary pharmacology & therapeutics.